Prothena Corporation plc (PRTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $419.01M
Last updated: Nov 17, 2026 at 11:06 AM ET
Prothena Corporation plc (PRTA) Competitors
The companies most similar to Prothena Corporation are PepGen (PEPG), Phathom Pharmaceuticals (PHAT) and Prelude Therapeutics (PRLD). By market cap, Prothena Corporation ranks 5th of the 13 companies on this page; Geron (GERN) is the largest at $622.98M.
Peer Comparison
PRTA's revenue growth of -74.3% is below the peer median of 11.8%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Prothena Corporation (PRTA) | $419.01M | N/A | 7.8x | -45.4% | N/A | -74.3% | 0.00% |
| PepGen Ltd (PEPG) | $410.98M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Phathom Pharmaceuticals Inc (PHAT) | $492.63M | N/A | 1.8x | -30.2% | 11.4% | 71.1% | 0.00% |
| Prelude Therapeutics Inc (PRLD) | $275.32M | N/A | 16.3x | -269.7% | N/A | 41.0% | 0.00% |
| Rocket Pharmaceuticals Inc (RCKT) | $256.82M | N/A | N/A | 0.0% | -2.3% | 0.0% | 0.00% |
| Gyre Therapeutics Inc. (GYRE) | $471.74M | N/A | 3.8x | -22.7% | N/A | 0.7% | 0.00% |
| Enanta Pharmaceuticals Inc (ENTA) | $320.09M | N/A | 4.8x | -96.9% | N/A | -21.6% | 0.00% |
| Protalix Biotherapeutics Inc (PLX) | $257.17M | 12.1x | 2.9x | 24.3% | N/A | 22.8% | 0.00% |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | $387.16M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Neurogene Inc (NGNE) | $495.37M | N/A | N/A | 0.0% | -28.5% | 0.0% | 0.00% |
| ProQR Therapeutics BV (PRQR) | $199.28M | N/A | 6.1x | -228.2% | N/A | 120.4% | 0.00% |
| Geron Corporation (GERN) | $622.98M | N/A | 2.9x | -22.0% | -7.4% | 27.4% | 0.00% |
| Precision BioSciences Inc (DTIL) | $288.76M | N/A | 4.4x | -85.6% | -38.3% | 37272.0% | 0.00% |
| Peer median | $353.62M | 12.1x | 4.1x | -22.4% | -7.4% | 11.8% | 0.00% |
Similar Companies
These are the 12 companies most similar to Prothena Corporation, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| PepGen Ltd (PEPG) | PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious... | PEPG competitors |
| Phathom Pharmaceuticals Inc (PHAT) | Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. | PHAT competitors |
| Prelude Therapeutics Inc (PRLD) | Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized... | PRLD competitors |
| Rocket Pharmaceuticals Inc (RCKT) | Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. | RCKT competitors |
| Gyre Therapeutics Inc. (GYRE) | Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases. | GYRE competitors |
| Enanta Pharmaceuticals Inc (ENTA) | Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. | ENTA competitors |
| Protalix Biotherapeutics Inc (PLX) | Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its... | PLX competitors |
| Contineum Therapeutics, Inc. Class A Common Stock (CTNM) | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies... | CTNM competitors |
| Neurogene Inc (NGNE) | Neurogene Inc. is an innovative biotechnology company at the forefront of developing advanced gene therapies for rare neurological disorders... | NGNE competitors |
| ProQR Therapeutics BV (PRQR) | ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. | PRQR competitors |
| Geron Corporation (GERN) | Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic... | GERN competitors |
| Precision BioSciences Inc (DTIL) | Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. | DTIL competitors |
Frequently Asked Questions About PRTA
Who are Prothena Corporation's main competitors?
The companies most similar to Prothena Corporation include PepGen (PEPG), Phathom Pharmaceuticals (PHAT), Prelude Therapeutics (PRLD), Rocket Pharmaceuticals (RCKT) and Gyre Therapeutics (GYRE), listed from the closest match.
Who is Prothena Corporation's biggest competitor?
Geron (GERN) is the largest of the similar companies at $622.98M; PepGen (PEPG) is the closest match by business profile, size, sector and industry.
How does PRTA stock compare with its competitors?
PRTA's P/S is 7.8x against a peer median of 4.1x; its net margin is -45.4% against a peer median of -22.4%.
Which of Prothena Corporation's competitors pays a higher dividend?
Prothena Corporation pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is Prothena Corporation bigger than its competitors?
No. Prothena Corporation is 5th by market cap among the 13 companies on this page; the largest is Geron (GERN) at $622.98M.
PRTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors